Skip to main content

Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost

Audiocasts - Original Research
Shardae Young, PharmD, BCPS
Clinical Pharmacy Specialist
Oncology
at VA Texas Valley Coastal Bend Health Care System
Harlingen,TX.
Shardae Young, PharmD, BCPS, Clinical Pharmacy Specialist, Oncology, VA Texas Valley Coastal Bend Health Care System, Harlingen,TX, discusses the clinical significance of her study, “Evaluating the Effects of a 14-Day Oral Chemotherapy Dispensing Protocol on Adherence, Toxicity, and Cost.”
Related Items
Ambulatory Hematology/Oncology Pharmacist Impact on Insurance Denials and Medication Access in an Academic Medical Center
JHOP - October 2027 Vol 17, No 5 published on August 17, 2026 in Original Research, Practical Issues in Pharmacy Management, Oncology Pharmacy Programs/Protocols
Outcomes in Early-Stage Triple-Negative Breast Cancer With Dose-Dense Doxorubicin and Cyclophosphamide as Part of Pembrolizumab-Based Regimens
JHOP - October 2027 Vol 17, No 5 published on August 7, 2026 in Original Research, Case Reports, Breast Cancer, Chemotherapy, Immunotherapy
Impact on Safety and Efficacy of Same-Day Administration of Pegfilgrastim in Patients Receiving Continuous 5-Fluorouracil Infusion
JHOP - April 2027 Vol 17, No 2 published on July 30, 2026 in Original Research, Adverse Events, Infusion Issues, Chemotherapy
Incidence of Hypersensitivity Reactions With Rapid Rituximab Infusions for Classical Hematology Indications
JHOP - June 2027 Vol 17, No 3 published on July 27, 2026 in Original Research, Adverse Events, Infusion Issues, Chemotherapy
Extending the Microbiologic Stability of Single-Dose Vials of High-Cost Medications to 28 Days Using a Closed-System Drug-Transfer Device
JHOP - December 2027 Vol 17, No 6 published on July 22, 2026 in Original Research, Cost of Care, Monoclonal Antibodies, Practical Issues in Pharmacy Management
Evaluation of Post-Nadir Granulocyte Colony-Stimulating Factor in Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy With a Hypomethylating Agent and Venetoclax
JHOP - February 2027 Vol 17, No 1 published on July 13, 2026 in Original Research, Chemotherapy, Leukemia
Improving Amivantamab Premedication Compliance by Implementing a Provider Notification
JHOP - February 2027 Vol 17, No 1 published on July 13, 2026 in Original Research, Lung Cancer, Infusion Issues, Oncology Pharmacy Programs/Protocols, Supportive Care
Comparison of Breakthrough Rates of Pneumocystis jirovecii Pneumonia in Adults With Malignancies Receiving Intravenous or Aerosolized Pentamidine for Prophylaxis
JHOP - April 2027 Vol 17, No 2 published on June 22, 2026 in Original Research, Adverse Events
Twice-Daily Bolus Versus Continuous Infusion Intravenous Tacrolimus for Prophylaxis of Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem-Cell Transplant Recipients
JHOP - June 2027 Vol 17, No 3 published on June 17, 2026 in Original Research, Transplant, Infusion Issues, Adverse Events
Incidence of PARP Inhibitor Adverse Events Between Germline Versus Somatic Homologous Recombination Mutations
JHOP - December 2026 Vol 16, No 6 published on June 15, 2026 in Original Research, Adverse Events, PARP Inhibitors, Dose Escalation/Reduction